Enanta sues Pfizer for infringement on Paxlovid, citing a patent it was granted a week ago

Earlier this year, Enanta Pharmaceuticals said it was entering the clinic with a COVID-19 treatment that might eventually challenge Pfizer’s antiviral Paxlovid.

Five months later, the biotech has revealed a more immediate challenge to Pfizer, filing suit in U.S. district court in Massachusetts claiming that the pharma giant infringed on a patent for its protease inhibitor COVID drug in creating Paxlovid.